Mounjaro and Menopause Weight Gain: Does It Work for Women Over 45?

To understand why Mounjaro can be so effective for menopausal women, it helps to understand what menopause actually does to your metabolism.

Before menopause, oestrogen plays a central role in regulating body fat distribution, insulin sensitivity, and appetite. As oestrogen levels decline — a process that begins in perimenopause, often in the mid-40s — several things happen simultaneously:

Fat redistribution. Fat that was stored around the hips and thighs begins to migrate to the abdomen. This visceral fat (fat stored around the internal organs) is metabolically active and carries a higher risk for cardiovascular disease, type 2 diabetes, and inflammation than subcutaneous fat.

Slower metabolism. Lower oestrogen levels reduce resting metabolic rate, meaning the body burns fewer calories at rest. This can amount to several hundred fewer calories per day compared to pre-menopausal metabolism.

Increased appetite signalling. Oestrogen interacts directly with hunger hormones including GLP-1, leptin, and ghrelin. When oestrogen falls, appetite regulation becomes less efficient — many women notice they feel hungrier, less satisfied after meals, and more prone to cravings.

Muscle loss. Menopause accelerates age-related muscle loss (sarcopenia), further reducing the body’s calorie-burning capacity.

Sleep disruption. Poor sleep — a hallmark of perimenopause and menopause — is directly linked to increased appetite, reduced satiety, and weight gain via hormonal pathways involving cortisol and ghrelin.

The result of all this is that approximately 70% of women experience meaningful weight gain during the menopause transition, and many find it far more difficult to lose than weight gained at earlier stages of life.

Mounjaro contains tirzepatide, a weekly injectable medication that works differently from older weight loss treatments. It is a dual GIP and GLP-1 receptor agonist — meaning it mimics two naturally occurring hormones that the gut releases in response to food.

These hormones act on the brain’s appetite centres to reduce hunger, increase satiety after eating, and slow gastric emptying (the rate at which food moves from the stomach to the intestine). The result is a significant, sustained reduction in calorie intake — without the experience of constant deprivation that makes traditional dieting unsustainable.

Tirzepatide also improves insulin sensitivity, lowers blood glucose and blood pressure, and reduces circulating cholesterol — all of which are particularly relevant for postmenopausal women, whose cardiometabolic risk increases after the loss of oestrogen’s protective effects.

Crucially, Mounjaro does not affect oestrogen or progesterone levels. It does not interfere with menopause itself, either accelerating or worsening it. Its hormonal mechanism is entirely separate from the reproductive system.

This is where the science becomes particularly interesting — and particularly relevant for women over 45.

The SURMOUNT trials: tirzepatide works regardless of menopausal stage

The SURMOUNT programme is the landmark clinical trial series that established tirzepatide’s weight loss efficacy. A detailed analysis published in the journal Obesity in 2025 examined outcomes specifically by menopausal stage, drawing on data from SURMOUNT-1, -3, and -4.

The findings were clear: tirzepatide produced significant body weight reductions in women at every stage of the menopause transition. In SURMOUNT-1, postmenopausal women lost an average of 23% of their body weight on tirzepatide at maximum dose, compared with just 3% on placebo. Waist circumference reductions of around 20cm were observed across menopausal subgroups — a particularly significant finding given the pattern of abdominal fat accumulation that defines menopausal weight gain.

Between 97% and 98% of women across all menopausal stages achieved at least 5% weight loss on tirzepatide, compared with 29–33% on placebo. These results confirm that menopause does not blunt tirzepatide’s effectiveness.

The Mayo Clinic/Lancet study: combining Mounjaro with HRT amplifies results

In January 2026, a landmark study led by Mayo Clinic researchers was published in The Lancet Obstetrics, Gynaecology, & Women’s Health. It is the first study to examine what happens when tirzepatide and menopausal hormone therapy (HRT) are used together — and the results are striking.

The study compared two groups of postmenopausal women with overweight or obesity who received tirzepatide for weight management over a median of 18 months:

• Women using HRT alongside tirzepatide lost 17% of their total body weight
• Women using tirzepatide alone lost 14% of their total body weight
• Women on HRT were more than twice as likely to achieve 20% or more total body weight loss (45% vs 18%)

This represents approximately 35% greater weight loss in women who combined HRT with Mounjaro compared to those taking Mounjaro alone.

The researchers, led by Dr Maria Daniela Hurtado Andrade of Mayo Clinic, noted that postmenopausal women on HRT achieved outcomes closely resembling those of premenopausal women — effectively closing the metabolic gap that menopause opens.

Several mechanisms may explain this synergy. There is emerging preclinical evidence suggesting that oestrogen may amplify the appetite-suppressing effects of GLP-1 signalling, with the two systems working together in the brain’s hypothalamus. Additionally, HRT reduces vasomotor symptoms (hot flushes, night sweats) that interfere with sleep and exercise capacity, which may improve adherence to the lifestyle changes that enhance Mounjaro’s effectiveness.

These findings are observational rather than from a randomised controlled trial, so causation cannot be definitively established — but they represent the best available evidence on this question and are consistent with earlier data from semaglutide studies showing similar trends.

Yes — but there is one important clinical consideration your doctor should be aware of.

Mounjaro slows gastric emptying, which affects how quickly medications are absorbed from the gut. This is relevant specifically for oral HRT tablets (such as Utrogestan or Gepretix, which contain progesterone, or oral oestrogen tablets). These medications may be absorbed more slowly or in reduced amounts when taken alongside Mounjaro.

This does not apply to all forms of HRT. Transdermal HRT — patches, gels, sprays, implants — absorbs directly through the skin and bypasses the digestive system entirely. It is unaffected by Mounjaro’s effect on gastric emptying. Similarly, hormonal coils (such as Mirena) release progesterone locally and are not affected.

If you are currently taking oral HRT and wish to start Mounjaro, the options are to switch to a transdermal formulation, use a hormonal coil for progesterone delivery, or discuss a dose adjustment with your doctor. At CutKilo, Dr Emil Gadimali will review your full medication history at your initial consultation and ensure your HRT and Mounjaro regimen are properly coordinated.

The eligibility criteria for Mounjaro are the same for menopausal and non-menopausal women:

• A BMI of 30 or above, or
• A BMI of 27 or above with at least one weight-related health co-morbidity

Many women in their late 40s and 50s meet these criteria. Menopausal weight gain — particularly the shift of fat to the abdomen — frequently brings previously healthy-weight women above these thresholds, or exacerbates existing conditions.

Women with a personal or family history of medullary thyroid cancer, or with certain other conditions, are not eligible. A thorough medical assessment at the point of prescribing is essential — which is why CutKilo operates as a doctor-led service from the outset.

Based on the SURMOUNT trial data and real-world evidence:

Average weight loss: Most postmenopausal women on tirzepatide can expect to lose between 15% and 23% of their starting body weight over 12–18 months, depending on dose and adherence.

Waist circumference: Reductions of 15–22cm in waist circumference have been documented in clinical trials for postmenopausal women — directly targeting the abdominal fat pattern most associated with menopause.

Metabolic benefits: Improvements in blood pressure, fasting glucose, cholesterol, and insulin sensitivity are consistently observed, reducing the elevated cardiometabolic risk that menopause brings.

If also on HRT: Based on the Mayo Clinic/Lancet study, women combining tirzepatide with HRT may achieve results comparable to premenopausal women — approximately 17–20% total body weight loss.

Results vary between individuals and depend on starting weight, dose, diet, activity levels, and adherence. At CutKilo, patients are reviewed monthly with dose adjustments overseen by Dr Emil Gadimali and nutritional support from dietitian Hanna Baldursdottir, ensuring you have the best possible clinical conditions to achieve your goals.

Weight loss during menopause is not just about the number on the scales. Because menopause accelerates both fat gain and muscle loss simultaneously, the scales can be misleading: you might be losing fat and gaining muscle, with little visible change in weight — or losing muscle alongside fat, with deceptive improvements in weight.

A DEXA body composition scan — available at our sister clinic, DEXA London on Harley Street — provides a precise breakdown of exactly how your body composition is changing: fat mass, lean muscle mass, visceral fat, and metabolic risk markers. For women on Mounjaro, this data is invaluable for understanding whether treatment is achieving the right kind of weight loss and whether nutritional support needs to be adjusted to preserve muscle mass.

Dr Emil Gadimali can incorporate DEXA scan data into your CutKilo treatment plan, creating a fully personalised approach to weight loss that no online pharmacy can replicate.

Does Mounjaro work for women going through menopause?
Yes. Clinical trial data from the SURMOUNT programme confirms that tirzepatide produces significant weight loss in women at all stages of the menopause transition, including postmenopause. A 2025 analysis found that postmenopausal women lost an average of 23% of their body weight on tirzepatide at the highest dose, with nearly identical results to premenopausal women.

Can I take Mounjaro and HRT together?
Yes, in most cases. However, if you take oral HRT tablets (particularly oral progesterone such as Utrogestan), Mounjaro’s effect on gastric emptying can reduce absorption. Switching to a transdermal HRT patch, gel, or spray avoids this issue entirely. Your CutKilo doctor will review your HRT regimen before prescribing.

Does Mounjaro affect hormone levels or make menopause symptoms worse?
No. Mounjaro works on GIP and GLP-1 receptors — entirely separate from the reproductive hormone system. It does not alter oestrogen or progesterone levels and does not affect menopause symptoms directly.

Will Mounjaro help with menopausal belly fat specifically?
Yes. Clinical trials show waist circumference reductions of 15–22cm in postmenopausal women — directly targeting the abdominal fat accumulation that is the hallmark of menopausal weight gain. Visceral fat (fat around the organs) is particularly responsive to tirzepatide.

Is combining HRT and Mounjaro better than Mounjaro alone?
Emerging evidence from a January 2026 Lancet study suggests yes. Women combining HRT with tirzepatide lost approximately 35% more weight than those on tirzepatide alone, and were more than twice as likely to achieve 20% or more total body weight loss. These are promising findings, though randomised controlled trial data are still needed.

Am I too old for Mounjaro?
No. There is no upper age limit for Mounjaro. Eligibility is determined by BMI and health status, not age. The SURMOUNT trials included women across all menopausal stages and found consistent efficacy regardless of reproductive stage.

How much does Mounjaro cost at CutKilo?
CutKilo pricing starts from £260 per month for the 2.5mg starting dose, up to £380 for the 15mg maintenance dose. All pricing includes a one-hour consultation with dietitian Hanna Baldursdottir and ongoing access to Dr Emil Gadimali. There is no subscription — you choose your plan monthly.

Ready to find out if Mounjaro is right for you? CutKilo is a doctor-led weight loss programme founded by Dr Emil Gadimali, practising physician at 86 Harley Street, London. Get started at cutkilo.com, or email us at info@cutkilo.com.